Abstracts tagged "Infection"

Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting
Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study
Zaki AbouZahr¹, Andrew Spiegelman², Maria Cantu³ and Bernard Ng⁴, ¹Baylor College of Medicine, Houston, TX, ²Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, ³Baylor College Of Medicine, Houston, TX, ⁴Michael E. DeBakey VA Medical Center, Houston, TX
Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
Abstract Number: 780 • 2013 ACR/ARHP Annual Meeting
Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants
Candace H. Feldman¹, Linda T. Hiraki², Francisco M. Marty³, Wolfgang C. Winkelmayer⁴, Jessica M. Franklin⁵, Daniel H. Solomon^6,7, Seoyoung C. Kim⁸ and Karen H. Costenbader⁹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ⁴Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are among the leading causes of hospitalization and mortality in patients with systemic lupus erythematosus (SLE); approximately 50% have a serious infection during…
Abstract Number: 730 • 2013 ACR/ARHP Annual Meeting
Cell-Mediated Immune Responses To Influenza and Herpesvirus Antigen Stimulation Are Conserved But Adversely Impacted By Immunosuppressive Therapy and Active Infection In Patients With Granulomatosis With Polyangiitis
John McKinnon¹, Robbie Mailliard², Dawn McClemens-McBride³, Donald Jones³, Charles Rinaldo Jr.⁴ and Kathleen Maksimowicz-McKinnon⁵, ¹Infectious Disease, Henry Ford Hospital, Detroit, MI, ²Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Infectious Diseases and Microbiology, Pathology, University of Pittsburgh, Pittsburgh, PA, ⁵Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Reactivation of chronic herpesvirus infections is not uncommon in immunosuppressed patients, including those with granulomatosis with polyangiitis (GPA). The effects of GPA disease and…
Abstract Number: 744 • 2013 ACR/ARHP Annual Meeting
Relationship Between Infectious Side Effects and Immunoglobulin Levels In The Maintenance Rituximab Vs Azathioprine For ANCA-Associated Vasculitides Trial
Loic Guillevin¹, Christian Pagnoux², Alexandre Karras³, Chahera Khouatra⁴, Olivier Aumaître⁵, Pascal Cohen⁶, Olivier Decaux⁷, Hélène Desmurs-Clavel⁸, Pierre Gobert⁹, Thomas Quemeneur¹⁰, Claire Blanchard-Delaunay¹¹, Pascal Godmer¹², Xavier Puechal¹³, Pierre-Louis Carron¹⁴, Pierre-Yves Hatron¹⁵, Nicolas Limal¹⁶, Mohamed Hamidou¹⁷, Francois Maurier¹⁸, Thomas Papo¹⁹, Matthias Büchler²⁰, Bernard Bonnotte²¹, Philippe Ravaud²² and Luc Mouthon²³, ¹Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ²Internal Medicine, Hôpital Cochin, PARIS, France, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴CHU Lyon, Lyon, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁸University of Lyon, LYON, France, ⁹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹⁰Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹¹Internal Medicine, Hôpital de Niort, Niort, France, ¹²Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ¹⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁵Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ¹⁹Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ²⁰Nephrology, University Hospital of Tours, TOURS, France, ²¹Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, ²²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ²³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: MAINRITSAN trial (NCT 00748644) results demonstrated that 500 mg of rituximab (RTX) every 6 months was superior to azathioprine (AZA) to maintain ANCA-associated–vasculitis (AAV)…
Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting
Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Carolina Mejia-Otero¹, Carlos J. Lozada² and Luis Arias-Urdaneta³, ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ³Rheumatology, Mount Sinai Medical Center, Miami Beach, FL
Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…
Abstract Number: 2679 • 2013 ACR/ARHP Annual Meeting
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication Use
Linda T. Hiraki¹, Candace H. Feldman², Mary Beth Son³, Jessica M. Franklin⁴, Michael A. Fischer⁴, Daniel H. Solomon⁵, Seoyoung C. Kim⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁵Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA
Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication UseBackground/Purpose: We investigated incidence rates…
Abstract Number: 531 • 2013 ACR/ARHP Annual Meeting
Influenza Infection Of MHC-I Transgenic Mice Reveals That Erap Is Necessary and Sufficient For Generation Of The B27-Specific Immunodominant Epitope
Ali Akram¹ and Robert Inman², ¹Institute of Medical Science and Department of Immunology, University of Toronto and University Health Network (UHN), Toronto, ON, Canada, ²Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Although HLA-B27 and ERAP are known to confer susceptibility to spondyloarthritis (SpA), the role of these elements in modulating host response to infection is…
Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis
Kevin L. Winthrop¹, Tanya Momtahen², Stefano Fiore³, Steven P. Weinstein⁴, Janet van Adelsberg⁵, Richard Wu⁶ and Neil Graham⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Program Direction, Sanofi, Bridgewater, NJ, ³Clinical Science, Sanofi, Bridgewater, NJ, ⁴Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁶BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…
Abstract Number: 445 • 2013 ACR/ARHP Annual Meeting
Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib
J. J. Gomez-Reino¹, A. Hazra², C. Fosser², S. Menon³, S. H. Zwillich², R. Riese² and S. Krishnaswami³, ¹Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Pfizer Inc, Groton, CT, ³Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Serious infections (requiring hospitalization or parenteral antibiotics; SIEs)…
Abstract Number: 2332 • 2013 ACR/ARHP Annual Meeting
Assessment of Lipid Changes and Infection Risk In Diabetic and Nondiabetic Patients With Rheumatoid Arthritis Treated With Tofacitinib
W. F. C. Rigby¹, L. Takiya², S. P. Wood³, H. Fan² and T. V. Jones², ¹Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Studies have shown an increased prevalence of diabetes mellitus…
Abstract Number: 376 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pneumococcal Infections After Immunisation With Pneumococcal Conjugate Vaccine Compared To Non-Vaccinated Inflammatory Arthritis Patients
Johanna Bengtsson¹, Pierre Geborek², Tore Saxne³, Martin Englund⁴, Ingemar F. Petersson⁴, Jan-Åke Nilsson⁵, Göran Jönsson⁶ and Meliha C. Kapetanovic⁷, ¹Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ²Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Lund Universoty, Dept of Clinical Sciences Lund, Section of Infectious Diseases, Lund, Sweden, ⁷Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
The risk of pneumococcal infections after immunisation with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patientsBackground/Purpose: The purpose was to examine the risk of…
Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Sima Ahadieh¹, Tina Checchio¹, Thomas Tensfeldt¹, Jonathan French², Sriram Krishnaswami¹, Richard Riese³, Sujatha Menon¹, Mary G. Boy¹ and Jamie L. Geier⁴, ¹Pfizer Inc., Groton, CT, ²Metrum Research Institute, Tariffville, CT, ³Pfizer Inc, Groton, CT, ⁴Epidemiology, Pfizer Inc., New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Catrina B. Scherrer¹, Anne AF Mannion², Diego Kyburz³, Markus Vogt⁴ and Ines A. Kramers-de Quervain¹, ¹Rheumatology, Schulthess Clinic, Zürich, Switzerland, ²Research Department, Schulthess Clinic, Zürich, Switzerland, ³Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁴Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…
Abstract Number: 1419 • 2012 ACR/ARHP Annual Meeting
Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up
Renata Baronaite Hansen¹ and Søren Jacobsen², ¹Department of Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ²Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of developing coronary heart disease as well as infections. Acute infections have been recognized…
Abstract Number: 1424 • 2012 ACR/ARHP Annual Meeting
Prevalence and Clinical Significance of Severe Infection in Patients with Systemic Lupus Erythematosus: Preliminary Data From Relesser (Registry of lupus of the Spanish Society of Rheumatology)
José M. Pego-Reigosa¹, Íñigo Rúa-Figueroa², Francisco J. López-Longo³, María Galindo⁴, Jaime Calvo-Alén⁵, Alejandro Olivé⁶, Loreto Horcada⁷, Esther Uriarte⁸, Eva Tomero⁹, Ana Sánchez-Atrio¹⁰, Carlos Montilla¹¹, José Rosas¹², Antonio Fernández-Nebro¹³, Paloma Vela¹⁴, Mercedes Freire¹⁵, Lucía Silva¹⁶, Elvira Díez-Álvarez¹⁷, Carlos Marras¹⁸, Antonio Zea¹⁹, Javier Narváez²⁰, Jose Luis Marenco²¹, Monica Fernández de Castro²², Olaia Fernánde-Berrizbeitia²³, Marian Gantes²⁴ and Celia Erausquin²⁵, ¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ²Rheumatology, Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain, ³Hospital Gregorio Marañón, Madrid, Spain, ⁴Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ⁵Reumatología, Hospital Sierrallana, Torrelavega, Spain, ⁶Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁷Reumatología, Hospital de Navarra, Spain, ⁸Reumatología, Hospital de Donosti, Donosti, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰Reumatología, Hospital Príncipe de Asturias, Madrid, Spain, ¹¹Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Reumatología, Hospital de Marina Baixa, Alicante, Spain, ¹³Reumatología, Hospital Carlos Haya, Malaga, Spain, ¹⁴Reumatología, Hospital General de Alicante, Alicante, Spain, ¹⁵Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹⁶Rheumatology, Hospital de Guadalajara, Guadalajara, Spain, ¹⁷Reumatología, Hospital de León, León, Spain, ¹⁸Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁹Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁰Reumatología, Hospital de Bellvitge, Barcelona, Spain, ²¹Rheumatology, Hospital de Valme, Seville, Spain, ²²Hospital Puerta del Hierro, Madrid, Spain, ²³Reumatología, Hospital de Basurto, Basurto, Spain, ²⁴Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ²⁵Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain
Background/Purpose: Infection is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Immunosuppression, comorbidities, and the disease itself makes patients with SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].